Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Modern Rheumatology
Published in: Modern Rheumatology 6/2010

01-12-2010 | Case Report

An attack of acute neuro-Behçet’s disease during the course of chronic progressive neuro-Behçet’s disease: report of two cases

Authors: Toshimichi Matsui, Takashi Ishida, Toshihiro Tono, Takuhiro Yoshida, Shun-ichi Sato, Shunsei Hirohata

Published in: Modern Rheumatology | Issue 6/2010

Login to get access

Abstract

A 29-year-old man and a 36-year-old man developed attacks of acute neuro-Behçet’s disease (NB) (right Horner’s syndrome and right hemiplegia and dysarthria, respectively) during the course of chronic progressive NB (acute on chronic). Although both patients recovered from acute NB after treatment with infliximab or corticosteroids, they continued to show manifestations of chronic progressive NB. It is suggested that acute NB and chronic progressive NB are different in their pathogenesis.
Literature
1.
2.
Hirohata S. Potential new therapeutic options for involvement of central nervous system in Behçet’s disease (Neuro-Behçet’s syndrome). Curr Rheumatol Rev. 2007;3:297–303.CrossRef
3.
Al-Araji A, Kidd DP. Neuro-Behçet’s disease: epidemiology, clinical characteristics, and management. Lancet. 2009;8:192–204.CrossRef
4.
Hirohata S, Isshi K, Oguchi H, Ohse T, Haraoka H, Takeuchi A, Hashimoto T. Cerebrospinal fluid interleukin-6 in progressive Neuro-Behçet’s syndrome. Clin Immunol Immunopathol. 1997;82:12–7.PubMedCrossRef
5.
Hirohata S, Suda H, Hashimoto T. Low-dose weekly methotrexate for progressive neuropsychiatric manifestations in Behçet’s disease. J Neurol Sci. 1998;159:181–5.PubMedCrossRef
6.
Ribi C, Sztajzel R, Delavelle J, Chizzolini C. Efficacy of TNF-α blockade in cyclophosphamide resistant neuro-Behcet disease. J Neurol Neurosurg Psychiatry. 2005;76:1733–5.PubMedCrossRef
7.
Pipitone N. Infliximab for the treatment of Neuro-Behcet’s disease: a case series and review of the literature. Arthritis Rheum. 2008;58:285–90.CrossRef
8.
Kikuchi H, Aramaki K, Hirohata S. Effect of infliximab in progressive Neuro-Behcet’s syndrome. J Neurol Sci. 2008;272:99–105.PubMedCrossRef
9.
Akman-Demir G, Tüzün E, Içöz S, Yeşilot N, Yentür SP, Kürtüncü M, Mutlu M, Saruhan-Direskeneli G. Interleukin-6 in neuro-Behçet’s disease: association with disease subsets and long-term outcome. Cytokine. 2008;44:373–6.PubMedCrossRef
10.
Haghighi AB, Ittehadi H, Nikseresht AR, Rahmati J, Poorjahromi SG, Pourabbas B, Nazarinia MA, Habibagahi Z, Fattahi MJ, Ghaderi A. CSF levels of cytokines in neuro-Behçet’s disease. Clin Neurol Neurosurg. 2009;111:507–10.PubMedCrossRef
11.
Saruhan-Direskeneli G, Yentür SP, Akman-Demir G, Işik N, Serdaroğlu P. Cytokines and chemokines in neuro-Behçet’s disease compared to multiple sclerosis and other neurological diseases. J Neuroimmunol. 2003;145:127–34.PubMedCrossRef
12.
Hirohata S. Histopathology of central nervous system lesions in Behçet’s disease. J Neurol Sci. 2008;267:41–7.PubMedCrossRef
Metadata
Title
An attack of acute neuro-Behçet’s disease during the course of chronic progressive neuro-Behçet’s disease: report of two cases
Authors
Toshimichi Matsui
Takashi Ishida
Toshihiro Tono
Takuhiro Yoshida
Shun-ichi Sato
Shunsei Hirohata
Publication date
01-12-2010
Publisher
Springer Japan
Published in
Modern Rheumatology / Issue 6/2010
Print ISSN: 1439-7595
Electronic ISSN: 1439-7609
DOI
https://doi.org/10.1007/s10165-010-0332-4

Other articles of this Issue 6/2010

Modern Rheumatology 6/2010 Go to the issue

Original Article

Etanercept response in patients with rheumatoid arthritis after secondary loss of efficacy of infliximab

Original Article

Comparison of low-field dedicated extremity magnetic resonance imaging with articular ultrasonography in patients with rheumatoid arthritis

Original Article

Elevated level of serum cystatin-C concentration is a useful predictor for myelosuppression induced by methotrexate for treatment of rheumatoid arthritis

Original Article

Better short-term clinical response to etanercept in Chinese than Caucasian patients with active ankylosing spondylitis

Erratum

Erratum to: Aspects of TNF inhibitor therapy in rheumatoid arthritis

Letter

Male presenting with bilateral ankle arthritis? Request a chest X-ray!
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits